المؤلفون: Maria Ochoa de Olza, Quincy Chu, Martin Gutierrez, Anna Spreafico, Ignacio Melero, Yan Feng, Palani Ravindran, Praveen Aanur, Filip de Vos, Kimberley M. Heinhuis, Michael Ong, Rui Wang, Victor Moreno, Richard D. Carvajal, Filippo de Braud, Jose Manuel Trigo, Stephen Leong, Anthony J. Olszanski, Mariano Provencio, Deanne Lathers

مصطلحات موضوعية: 0301 basic medicine, Adult, Male, Cancer Research, medicine.medical_specialty, Combination therapy, Ipilimumab, Gastroenterology, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Pharmacokinetics, Internal medicine, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, medicine, Clinical endpoint, Biomarkers, Tumor, Humans, Adverse effect, Aged, Aged, 80 and over, business.industry, Antibodies, Monoclonal, Middle Aged, Receptors, OX40, Rash, 030104 developmental biology, Nivolumab, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Pharmacodynamics, Female, medicine.symptom, business, medicine.drug

الوصف: Purpose: This phase I/IIa study (NCT02737475) evaluated the safety and activity of BMS-986178, a fully human OX40 agonist IgG1 mAb, ± nivolumab and/or ipilimumab in patients with advanced solid tumors. Patients and Methods: Patients (with non–small cell lung, renal cell, bladder, other advanced cancers) received BMS-986178 (20–320 mg) ± nivolumab (240–480 mg) and/or ipilimumab (1–3 mg/kg). The primary endpoint was safety. Additional endpoints included immunogenicity, pharmacodynamics, pharmacokinetics, and antitumor activity per RECIST version 1.1. Results: Twenty patients received BMS-986178 monotherapy, and 145 received combination therapy in various regimens (including two patients receiving nivolumab monotherapy). With a follow-up of 1.1 to 103.6 weeks, the most common (≥5%) treatment-related adverse events (TRAEs) included fatigue, pruritus, rash, pyrexia, diarrhea, and infusion-related reactions. Overall, grade 3–4 TRAEs occurred in one of 20 patients (5%) receiving BMS-986178 monotherapy, six of 79 (8%) receiving BMS-986178 plus nivolumab, zero of two receiving nivolumab monotherapy, six of 41 (15%) receiving BMS-986178 plus ipilimumab, and three of 23 (13%) receiving BMS-986178 plus nivolumab plus ipilimumab. No deaths occurred. No dose-limiting toxicities were observed with monotherapy, and the MTD was not reached in either the monotherapy or the combination escalation cohorts. No objective responses were seen with BMS-986178 alone; objective response rates ranged from 0% to 13% across combination therapy cohorts. Conclusions: In this study, BMS-986178 ± nivolumab and/or ipilimumab appeared to have a manageable safety profile, but no clear efficacy signal was observed above that expected for nivolumab and/or ipilimumab.

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4727cae38dadb98f78308d4a27d16b8fTest
https://hdl.handle.net/10668/16546Test

المؤلفون: Sattva S. Neelapu, Theodore F. Logan, Izidore S. Lossos, Vincent Ribrag, Charles Herbaux, Walter J. Urba, Yoshinobu Koguchi, John M. Timmerman, Caron A. Jacobson, Satyendra Suryawanshi, John E. Godwin, Ronald Levy, Roch Houot, Andrew D. Zelenetz, Cecilia Carpio, Deanne Lathers, Gilles Salles, Jaclyn Neely, Yali Liu, Radhakrishnan Ramchandren

المساهمون: Institut Català de la Salut, [Timmerman J] UCLA Medical Center, Los Angeles, California. [Herbaux C] Centre Hospitalier Régional Universitaire de Lille, Lille, France. [Ribrag V] Institut Gustave Roussy, Villejuif, France. [Zelenetz AD] Memorial Sloan Kettering Cancer Center, New York, New York. [Houot R] CHU Rennes, Service Hématologie Clinique, Rennes, France. INSERM, Unité dʼInvestigation Clinique, Rennes, France. [Neelapu SS] The University of Texas MD Anderson Cancer Center, Houston, Texas. [Carpio C] Vall dʼHebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, California State University [Los Angeles] (CAL STATE LA), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut Gustave Roussy (IGR), Memorial Sloane Kettering Cancer Center [New York], CHU Pontchaillou [Rennes], Microenvironment, Cell Differentiation, Immunology and Cancer (MICMAC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), The University of Texas M.D. Anderson Cancer Center [Houston], Indiana University System, University of Miami Leonard M. Miller School of Medicine (UMMSM), Providence Cancer Center, Hospices Civils de Lyon (HCL), Dana-Farber Cancer Institute [Boston], Universitat Autònoma de Barcelona (UAB), Bristol-Myers Squibb Company, Stanford School of Medicine [Stanford], Stanford Medicine, Stanford University-Stanford University, Bristol-Myers SquibbBristol-Myers Squibb, Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Jonchère, Laurent

المصدر: Scientia
American Journal of Hematology
American Journal of Hematology, Wiley, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩
American Journal of Hematology, 2020, 95 (5), pp.510-520. ⟨10.1002/ajh.25757⟩
Recercat: Dipósit de la Recerca de Catalunya
Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname

مصطلحات موضوعية: [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, Follicular lymphoma, Medicaments antineoplàstics - Ús terapèutic, Gastroenterology, 0302 clinical medicine, Antineoplastic Agents, Immunological, immune system diseases, hemic and lymphatic diseases, Other subheadings::/therapeutic use [Other subheadings], Research Articles, biology, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Antibodies, Monoclonal, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, Middle Aged, Progression-Free Survival, 3. Good health, neoplasias::neoplasias por tipo histológico::linfoma::linfoma no Hodgkin::linfoma de células B::linfoma de células B grandes difuso [ENFERMEDADES], 030220 oncology & carcinogenesis, Rituximab, Female, Lymphoma, Large B-Cell, Diffuse, Antibody, [SDV.IMM.IMM] Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.drug, Research Article, medicine.medical_specialty, Cèl·lules B - Tumors - Tractament, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, Refractory, [SDV.CAN] Life Sciences [q-bio]/Cancer, Neoplasms::Neoplasms by Histologic Type::Lymphoma::Lymphoma, Non-Hodgkin::Lymphoma, B-Cell::Lymphoma, Large B-Cell, Diffuse [DISEASES], Internal medicine, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], medicine, Humans, In patient, Progression-free survival, Aged, business.industry, Otros calificadores::/uso terapéutico [Otros calificadores], [SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/Immunotherapy, medicine.disease, Lymphoma, Discontinuation, biology.protein, business, 030215 immunology

الوصف: Limfoma de cèl·lules B; Urelumab Linfoma de células B; Urelumab B-cell lymphoma; Urelumab Urelumab, a fully human, non-ligand binding, CD137 agonist IgG4 monoclonal antibody, enhances T-cell and natural killer-cell antitumor activity in preclinical models, and may enhance cytotoxic activity of rituximab. Here we report results in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and other B-cell lymphomas, in phase 1 studies evaluating urelumab alone (NCT01471210) or combined with rituximab (NCT01775631). Sixty patients received urelumab (0.3 mg/kg IV Q3W, 8 mg IV Q3W, or 8 mg IV Q6W); 46 received urelumab (0.1 mg/kg, 0.3 mg/kg, or 8 mg IV Q3W) plus rituximab 375 mg/m2 IV QW. The maximum tolerated dose (MTD) of urelumab was determined to be 0.1 mg/kg or 8 mg Q3W after a single event of potential drug-induced liver injury occurred with urelumab 0.3 mg/kg. Treatment-related AEs were reported in 52% (urelumab: grade 3/4, 15%) and 72% (urelumab + rituximab: grade 3/4, 28%); three led to discontinuation (grade 3 increased AST, grade 4 acute hepatitis [urelumab]; one death from sepsis syndrome [urelumab plus rituximab]). Objective response rates/disease control rates were 6%/19% (DLBCL, n = 31), 12%/35% (FL, n = 17), and 17%/42% (other B-cell lymphomas, n = 12) with urelumab and 10%/24% (DLBCL, n = 29) and 35%/71% (FL, n = 17) with urelumab plus rituximab. Durable remissions in heavily pretreated patients were achieved; however, many were observed at doses exceeding the MTD. These data show that urelumab alone or in combination with rituximab demonstrated manageable safety in B-cell lymphoma, but the combination did not enhance clinical activity relative to rituximab alone or other current standard of care. Research funding from Bristol-Myers Squibb, Kite/Gilead, Merck, and Spectrum Pharmaceuticals.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f29dadecdd66de9605b92ac4df56b311Test
https://hdl.handle.net/11351/6523Test

المؤلفون: Q.S-C. Chu, Penny Phillips, Georgia Kollia, Deanne Lathers, Lee M. Krug, Paula M. Fracasso, Natasha B. Leighl, J.R. Jackson, Neal Ready, Charles M. Rudin, P. Basciano, G. Kolaitis, Ben Markman, Daphne Williams

المصدر: Annals of Oncology. 27:vi494

مصطلحات موضوعية: 0301 basic medicine, business.industry, medicine.drug_class, Hematology, Monoclonal antibody, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Relapsed refractory, Immunology, Cancer research, Medicine, Fucosyl GM1, Non small cell, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_________::718f805a8ebb7e5d8b97529de186b95dTest
https://doi.org/10.1093/annonc/mdw389.05Test

المؤلفون: Georgia Kollia, K. Urbanska, S. Tannenbaum-Dvir, Stephen Clarke, C.M.L. van Herpen, G. Kolaitis, Deanne Lathers, Q.S-C. Chu, Daphne Williams, Neal Ready, Natasha B. Leighl, Ben Markman, C. Darby, P. Basciano, Rosalyn A. Juergens

المصدر: Web of Science

مصطلحات موضوعية: 0301 basic medicine, business.industry, medicine.drug_class, Hematology, Monoclonal antibody, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Relapsed refractory, Cancer research, Medicine, Fucosyl GM1, Non small cell, Nivolumab, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be4cec939479c65c49e02677b58f4942Test
https://publons.com/wos-op/publon/18455203Test/